If you have been reading about lipolysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-20. Numbers and descriptions here follow the published literature rather than marketing material.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
== Diplomatenkennzeichen == Auf Anfrage wird Angehörigen des diplomatischen oder konsularischen Dienstes ein Diplomatenkennzeichen zugeteilt. Die Buchstaben-/Ziffernkombination dieses Kennzeichens beginnt mit den Buchstaben CD, gefolgt von einem kurzen Strich, zwei weiteren Buchstaben und drei Ziffern. Es gibt weder eine vorangestellte Ziffer noch einen vorangestellten Buchstaben.
Liselotte Schramm-Heckmann (* 12. August 1904 in Duisburg; † 21. Januar 1995 in Erkrath) war eine deutsche Bildnis-, Figuren- und Landschafts-Malerin sowie Kostümzeichnerin und Ehefrau des Künstlers Werner Schramm. Sie gehörte zu der internationalen Künstler-Gruppe der „Peintres de la Réalité“, die sich später zum „Mouvement Trompe-l'œil/Réalité“ entwickelte und war Mitglied im Verein Düsseldorfer Künstlerinnen sowie Ehrenmitglied der Arbeitsgemeinschaft Düsseldorfer Künstlervereinigungen.
== Leben == Liselotte Schramm-Heckmann war die Tochter von Rheinhold Heckmann (1873–1964) und Amélie Heckmann geb. Schumm (1880–1967). Rheinhold Heckmann war in Berlin aufgewachsen und zog 1888 nach Duisburg, dann 1897 nach Bonn, wo er Amélie Schumm kennenlernte. Liselotte Schramm-Heckmann wurde im Jahr 1904 in Duisburg geboren und hatte zwei Brüder: Carl-Justus (1902–1993) und Fritz (* 1907). Die drei Kinder wuchsen zusammen in Duisburg auf, wo der Vater arbeitete. Schon früh versuchte sich Liselotte Schramm-Heckmann im Malen und Zeichnen. Ihre Mutter unterstützte sie dabei schon in jungen Jahren, beeinflusst von Hans Thoma und Albert Schweitzer ermöglichte sie ihr Zeichenunterricht bei Fritz Linde, wo sie 10-jährig den 16-jährigen Werner Schramm kennenlernte. Sie trafen sich von da an zum gemeinsamen Zeichnen, Malen und Schneiden von Scherenschnitten. Im Jahr 1915 entstand beispielsweise eine Zeichnung von Werner Schramm, die Liselotte Heckmann im Alter von zehn Jahren zeigt. Noch während des Ersten Weltkriegs organisierte Amélie Heckmann am Gymnasium, wo Fritz Linde unterrichtet hatte und welches Werner Schramm besuchte, eine Ausstellung zum Gedenken an den gefallenen Kunstlehrer Fritz Linde und wurde dabei von dessen Schüler Werner Schramm unterstützt. Das Ende des Ersten Weltkrieges erlebte Liselotte Schramm-Heckmann mit 14 Jahren. Sie beschrieb die Zeit danach als „schwere Zeit mit Hunger und Ruhr, Bürgerkrieg und passivem Widerstand gegen die Besatzung“.
Im Jahr 1921 beendete sie ihre Schulzeit an der Höheren Töchterschule und konzentrierte sich dann auf das Studium der Malerei. Hans Rilke schätzte sie als Lehrer sehr, er sei „sehr vielseitig, versuchte nicht, seine Schüler in eine bestimmt Richtung zu drängen, sondern ließ sie sich nach ihrer persönlichen Weise entfalten.“ Seinen sozialkritischen Arbeiten hingegen brachte sie wenig Sympathie entgegen. Später lernte sie auch bei Marie Henrici in Alsbach. Ab 1923 unterstützte Liselotte Heckmann als Kostümzeichnerin am Schauspielhaus Düsseldorf und an anderen Bühnen die Arbeit ihres späteren Ehemannes Werner Schramm, der dort als Bühnenbildner tätig war. Bis 1925 waren sie an Bühnen in Hamborn, Mönchengladbach, Oberhausen und Gladbeck tätig. Im Jahre 1925 heirateten sie. Beide beendeten die Arbeiten am Düsseldorfer Schauspielhaus, um sich von nun an nur noch der freien Malerei zu widmen. Von 1925 bis 1926 lebten sie zu Studienzwecken zunächst in Fiesole bei Florenz und später von 1926 bis 1931 in Meudon bei Paris. 1931 zog das Ehepaar nach Düsseldorf und stellte in den folgenden Jahren ihre Kunst im In- und Ausland (u. a. in Düsseldorf, und Paris/Frankreich) aus. U. a. hatten sie 1939 in Mülheim an der Ruhr im Städtischen Museum eine Ausstellung. In der Zeit des Nationalsozialismus war Liselotte Schramm-Heckmann obligatorisch Mitglied der Reichskammer der bildenden Künste. 1953 nahmen sie in der DDR an der Dritten Deutschen Kunstausstellung in Dresden teil.
Sources: de.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.